SM
PTGX icon

SG3 Management’s Protagonist Therapeutics PTGX Stock Holding History

SG3 Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$316K – 1231
2021
Q3 		$177K Buy
+10,000
New +$426K 0.01% 803

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SG3 Management's PTGX Position: Q4 2021 in Review

SG3 Management sold out of Protagonist Therapeutics (PTGX) in Q4 2021, closing a stake of 10,000 shares — an estimated $316K sold.

SG3 Management first reported a position in PTGX in Q3 2021 and held it in 1 quarter. The position peaked at $177K in Q3 2021. 149 funds tracked by Wall St. Rank hold PTGX as of Q4 2021.

  • SG3 Management reported no remaining Protagonist Therapeutics position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 10,000 Protagonist Therapeutics shares in Q4 2021, an estimated $316K.
  • SG3 Management first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 1 quarter.
  • SG3 Management's Protagonist Therapeutics position peaked at $177K in Q3 2021.
  • 149 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.